Interview with Dr. Andreas Rimner: The Role of Radiotherapy in the Treatment of Stage III Thymoma

Interview with Dr. Andreas Rimner: The Role of Radiotherapy in the Treatment of Stage III Thymoma

Thymoma is one of the most common primary tumors in the anterior mediastinum, representing a group of diseases originating from different thymic epithelial cells, characterized by unique clinical and pathological features, often accompanied by various paraneoplastic syndromes. During the "Multidisciplinary Oncology Committee" session held at the 2023 European Lung Cancer Congress (ELCC), several experts discussed the treatment strategies for Stage III thymoma based on a case study. Dr. Andreas Rimner from Memorial Sloan Kettering Cancer Center presented on "The Timing of Radiotherapy in the Treatment of Stage III Thymoma." In an interview with Oncology Frontier, Andreas Rimner shares insights into the role of radiotherapy in the treatment of Stage III thymoma.
Incorporating Cytarabine in Pre-treatment for Haploidentical Stem Cell Transplantation in Extramedullary Acute Leukemia: Safety and Efficacy

Incorporating Cytarabine in Pre-treatment for Haploidentical Stem Cell Transplantation in Extramedullary Acute Leukemia: Safety and Efficacy

Allogeneic hematopoietic stem cell transplantation is among the most effective methods for treating malignant hematopoietic tumors. However, for extramedullary leukemia, even with high-intensity chemotherapy and transplantation, the recurrence rate remains high. To improve the prognosis, it's essential to optimize the pre-treatment plan and reduce recurrence.At this EBMT annual meeting,Dr. Min Xiong from Hebei Yanda Ludaopei Hospital reported a clinical study (Abstract No.: 1100). Results indicate that a pre-treatment regimen incorporating cytarabine for haploidentical hematopoietic stem cell transplantation to treat extramedullary leukemia is both safe and effective. We've invited Dr. Xiong  for a  interpretation of this research. This retrospective analysis was conducted on 36 patients with extramedullary leukemia who underwent haploidentical allogeneic hematopoietic stem cell transplantation at Beijing Ludaopei Hospital from August 2019 to March 2022. The pre-treatment regimen used BU/CY in 14 cases (38.9%) and TBI/CY in 22 cases (61.1%), combined with cytarabine (5 mg/kg, on days -3 and -2). The overall survival (OS), disease-free survival (DFS), and transplant-related mortality (TRM) of the patients were assessed.
Dr.  Hui Wang: Unlocking a New Approach to MRD Testing in Acute Myeloid Leukemia

Dr.  Hui Wang: Unlocking a New Approach to MRD Testing in Acute Myeloid Leukemia

The 49th European Bone Marrow Transplantation Annual Meeting (EBMT 2023) took place in Paris, France, from April 23 to 26, 2023. Experts and scholars from various countries gathered to present exciting advancements in research. In the field of blood tests, the fifty-year anniversary of flow cytometry coincided with this year's conference. Over the past half-century, this technology has become an indispensable tool in the diagnosis and follow-up of hematological malignancies. Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults, and the detection of Minimal Residual Disease (MRD) plays a crucial role in clinical treatment and prognosis assessment, despite encountering various technical challenges. With the release of two significant expert consensus statements by the European Leukemia Network (ELN) in 2018 and 2021, technical issues related to AML MRD detection by Multiparameter Flow Cytometry (MFC) were discussed, making this research once again the focus of the hematology field.
Dr. Xingyu Cao: Post-transplant maintenance therapy with Chidamide in T-ALL patients is expected to reduce relapse and improve survival  

Dr. Xingyu Cao: Post-transplant maintenance therapy with Chidamide in T-ALL patients is expected to reduce relapse and improve survival  

Acute T-cell lymphoblastic leukemia (T-ALL) is a highly heterogeneous malignant tumor of the hematopoietic system caused by the malignant transformation of T-cell precursors. It has significant differences from B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in clinical features, cellular genetics, molecular biology, and abnormal signal transduction pathways. T-ALL accounts for 10%-15% in children and 20%-25% in adults. Adult T-ALL has a poor prognosis due to primary chemotherapy resistance and early recurrence, with a 5-year event-free survival rate of only 20%-50%. The main challenge for T-ALL patients after transplantation is recurrence. From April 23-26, 2023, the EBMT Annual Meeting was grandly held in Paris, France. At the meeting, Dr. Cao Xingyu from Hebei Yanda Ludao Pei Hospital reported a clinical study (abstract number: 351), which suggested that the use of Chidamide for maintenance treatment might improve the survival of T-ALL patients after allogeneic hematopoietic stem cell transplantation (Allo-HSCT).
Two Studies of Dr. Yong Xu’s Team at the 2023 EAU Congress, Provided New Insights into Prostate Cancer Biopsies

Two Studies of Dr. Yong Xu’s Team at the 2023 EAU Congress, Provided New Insights into Prostate Cancer Biopsies

The 38th Annual Congress of the European Association of Urology (EAU23) took place in Milan, Italy, from March 10 to 13, 2023. EAU Congress is one of the most highly anticipated urology conferences in Europe and worldwide, attracting over 15,000 urology experts from around the globe each year. At this year's EAU Congress, Dr. Yong Xu's team from the Second Hospital of Tianjin Medical University had two related studies on prostate cancer selected for presentation, exploring radical excision surgery without biopsies for highly suspicious prostate cancer patients and comparing regional saturation biopsies to targeted biopsies for initial evaluation of suspected prostate cancer patients. These research findings offer new perspectives on prostate cancer biopsies and non-invasive diagnostics.
The urology team of West China Hospital has selected multiple studies for the 2023 EAU conference

The urology team of West China Hospital has selected multiple studies for the 2023 EAU conference

The 38th European Association of Urology (EAU23) Annual Meeting took place from March 10th to 13th, 2023, in Milan, Italy, the fashion capital of the world. The EAU Annual Meeting is one of the most closely watched urological conferences in Europe and even globally, attracting over 15,000 urology experts from around the world each year. At this conference, West China Hospital of Sichuan University reported Several studies.
Dr. Daobin Zhou’s Team: Zanubrutinib combined with R-CHOP regimen demonstrates efficacy and safety in primary treatment of Intravascular Large B-Cell

Dr. Daobin Zhou’s Team: Zanubrutinib combined with R-CHOP regimen demonstrates efficacy and safety in primary treatment of Intravascular Large B-Cell

Intravascular Large B-Cell Lymphoma (IVLBCL) is a subtype of large B-cell lymphoma, characterized by large tumor B-cells aggregating inside blood vessels. This disease is extremely rare and highly malignant, often involving the central nervous system, lungs, and skin. Its prognosis is poor and clinical treatment challenging. At the recently concluded 28th European Hematology Association (EHA) Annual Meeting, a study (Abstract Number: P1185) from Dr. Daobin Zhou's team at Peking Union Medical College Hospital was selected. This study evaluated the efficacy and safety of the Zanubrutinib combined with R-CHOP regimen in treating initial IVLBCL, attracting widespread attention. To further understand this study, the Oncolgy Fronter invited Dr. Zhou for a detailed interpretation and analysis, summarized as follows: IVLBCL is a rare type of aggressive B-cell lymphoma that does not form a tumor mass. Its diagnosis is difficult and lacks an established standard treatment. Zanubrutinib is a novel Bruton kinase inhibitor. Recent studies have shown that Zanubrutinib has good therapeutic effects in B-cell lymphomas originating from activated B-cells, those with dual expression, and those with MYD88 mutations.
Dr. Huaqing Wang: Primary Mediastinal B-Cell Lymphoma (PMBCL) Benefits More Significantly from Axi-Cel Treatment

Dr. Huaqing Wang: Primary Mediastinal B-Cell Lymphoma (PMBCL) Benefits More Significantly from Axi-Cel Treatment

From June 8th to 11th, 2023, the 28th European Hematology Association Congress (EHA) will take place in Frankfurt, Germany, in both online and offline formats, organized by the European Hematology Society. As the largest international conference in the field of European hematology, the EHA Congress will cover various scientific topics, clinical and basic research, benign and malignant hematology, and discuss the latest developments in the field of hematology. At this year's EHA Congress, a study from Italy (abstract S231) explored the differences in the efficacy and survival outcomes of CAR-T cell therapy for different subtypes of B-cell lymphoma patients, drawing significant attention. To gain a deeper understanding of this study, Oncology Frontier conducted an exclusive interview with Professor Wang Huaqing from Tianjin People's Hospital of Nankai University, who provided detailed insights into the research.